JP2018533582A5 - - Google Patents

Download PDF

Info

Publication number
JP2018533582A5
JP2018533582A5 JP2018522126A JP2018522126A JP2018533582A5 JP 2018533582 A5 JP2018533582 A5 JP 2018533582A5 JP 2018522126 A JP2018522126 A JP 2018522126A JP 2018522126 A JP2018522126 A JP 2018522126A JP 2018533582 A5 JP2018533582 A5 JP 2018533582A5
Authority
JP
Japan
Prior art keywords
cancer
use according
pharmaceutically acceptable
acceptable salt
acid ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018522126A
Other languages
English (en)
Japanese (ja)
Other versions
JP6833844B2 (ja
JP2018533582A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/059342 external-priority patent/WO2017075363A1/en
Publication of JP2018533582A publication Critical patent/JP2018533582A/ja
Publication of JP2018533582A5 publication Critical patent/JP2018533582A5/ja
Application granted granted Critical
Publication of JP6833844B2 publication Critical patent/JP6833844B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018522126A 2015-10-30 2016-10-28 アルギナーゼ活性を阻害する組成物及び方法 Active JP6833844B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562248632P 2015-10-30 2015-10-30
US62/248,632 2015-10-30
US201662281964P 2016-01-22 2016-01-22
US62/281,964 2016-01-22
US201662323034P 2016-04-15 2016-04-15
US62/323,034 2016-04-15
PCT/US2016/059342 WO2017075363A1 (en) 2015-10-30 2016-10-28 Compositions and methods for inhibiting arginase activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021014795A Division JP7032583B2 (ja) 2015-10-30 2021-02-02 アルギナーゼ活性を阻害する組成物及び方法

Publications (3)

Publication Number Publication Date
JP2018533582A JP2018533582A (ja) 2018-11-15
JP2018533582A5 true JP2018533582A5 (https=) 2020-03-19
JP6833844B2 JP6833844B2 (ja) 2021-02-24

Family

ID=58631120

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018522126A Active JP6833844B2 (ja) 2015-10-30 2016-10-28 アルギナーゼ活性を阻害する組成物及び方法
JP2021014795A Expired - Fee Related JP7032583B2 (ja) 2015-10-30 2021-02-02 アルギナーゼ活性を阻害する組成物及び方法
JP2022025334A Withdrawn JP2022071010A (ja) 2015-10-30 2022-02-22 アルギナーゼ活性を阻害する組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021014795A Expired - Fee Related JP7032583B2 (ja) 2015-10-30 2021-02-02 アルギナーゼ活性を阻害する組成物及び方法
JP2022025334A Withdrawn JP2022071010A (ja) 2015-10-30 2022-02-22 アルギナーゼ活性を阻害する組成物及び方法

Country Status (36)

Country Link
US (4) US10065974B2 (https=)
EP (3) EP3693375B1 (https=)
JP (3) JP6833844B2 (https=)
KR (2) KR20220118559A (https=)
CN (4) CN108271371B (https=)
AU (3) AU2016343656B2 (https=)
BR (3) BR112018008746B1 (https=)
CA (1) CA3003271A1 (https=)
CL (4) CL2018001134A1 (https=)
CO (1) CO2018004750A2 (https=)
CR (3) CR20210390A (https=)
CY (1) CY1123557T1 (https=)
DK (2) DK3368541T3 (https=)
EA (1) EA038276B1 (https=)
EC (1) ECSP18040250A (https=)
ES (3) ES2910928T3 (https=)
HR (1) HRP20201046T1 (https=)
HU (1) HUE054972T2 (https=)
IL (3) IL258731B (https=)
LT (1) LT3368541T (https=)
MA (2) MA50636A (https=)
MD (1) MD3368541T2 (https=)
MX (1) MX2018005294A (https=)
MY (1) MY201783A (https=)
NZ (1) NZ742742A (https=)
PH (2) PH12022551082A1 (https=)
PL (1) PL3368541T3 (https=)
PT (1) PT3368541T (https=)
RS (1) RS60695B1 (https=)
SG (4) SG11201802961PA (https=)
SI (1) SI3368541T1 (https=)
SM (1) SMT202000469T1 (https=)
TW (3) TWI775556B (https=)
UA (1) UA125289C2 (https=)
WO (1) WO2017075363A1 (https=)
ZA (4) ZA201803556B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201503168VA (en) 2010-04-22 2015-06-29 Mars Inc Inhibitors of arginase and their therapeutic applications
HRP20160305T1 (hr) 2010-10-26 2016-07-01 Mars, Incorporated Borati kao inhibitori arginaze
SG11201802961PA (en) 2015-10-30 2018-05-30 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
JP2020502259A (ja) * 2016-11-08 2020-01-23 カリセラ バイオサイエンシズ,インコーポレイテッド アルギナーゼ阻害剤併用療法
CN114989205A (zh) * 2016-12-22 2022-09-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
KR20200008578A (ko) * 2017-05-12 2020-01-28 칼리테라 바이오사이언시즈, 인코포레이티드 (3R,4S)-3-아세트아미도-4-알릴-N-(tert-부틸)피롤리딘-3-카복스아미드의 제조방법
CN111491937A (zh) * 2017-12-22 2020-08-04 广东新契生物医药科技有限公司 作为精氨酸酶抑制剂的杂环化合物
CN117186134A (zh) 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
AU2019229978B2 (en) 2018-03-05 2024-05-30 Arcus Biosciences, Inc. Arginase inhibitors
EP3765006A4 (en) * 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
WO2019186497A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
WO2019245890A1 (en) 2018-06-20 2019-12-26 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
TWI828800B (zh) 2018-11-16 2024-01-11 美商阿克思生物科學有限公司 Arg1及/或arg2之抑制劑
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
EP3897622B1 (en) 2018-12-18 2026-01-14 Merck Sharp & Dohme LLC Arginase inhibitors and methods of use
WO2020160707A1 (en) * 2019-02-06 2020-08-13 Guangdong Newopp Biopharmaceuticals Co., Ltd. Alkylboronic acids as arginase inhibitors
CA3138544A1 (en) * 2019-05-02 2020-11-05 Aclaris Therapeutics, Inc. Substituted pyrrolopyridines as jak inhibitors
WO2021014380A1 (en) * 2019-07-23 2021-01-28 Astrazeneca Ab Arginase inhibitors and methods of use thereof
CN110615753A (zh) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
AU2020384481B2 (en) 2019-11-12 2025-12-11 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereof
EP4087583B1 (en) * 2020-01-07 2026-04-22 Merck Sharp & Dohme LLC Arginase inhibitors and methods of use
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
CR20230057A (es) 2020-07-02 2023-08-15 Incyte Corp Compuestos tríciclicos de urea como inhibidores de jak2 v617f
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
TW202216662A (zh) 2020-07-17 2022-05-01 美商英塞特公司 製備精胺酸酶抑制劑及其合成中間物之方法
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
AU2023235313A1 (en) 2022-03-17 2024-10-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US20240190876A1 (en) 2022-10-21 2024-06-13 Incyte Corporation Tricyclic Urea Compounds As JAK2 V617F Inhibitors
JP2026509874A (ja) 2023-03-13 2026-03-25 インサイト・コーポレイション キナーゼ阻害剤としての二環式尿素
US20260098044A1 (en) 2024-10-04 2026-04-09 Incyte Corporation Tricyclic heteroaryl compounds as inhibitors of tyk2 and/or jak1

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
CA2415174A1 (en) 2000-07-06 2002-01-17 Thomas W. Bell Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2007005620A2 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Arginase ii: a target treatment of aging heart and heart failure
CN101755130B (zh) 2007-07-12 2012-10-17 山洋电气株式会社 双重反转式轴流鼓风机
JP5421272B2 (ja) * 2007-10-12 2014-02-19 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 眼病治療のための組成物及び方法
US20110129456A1 (en) * 2008-05-05 2011-06-02 Yaolin Wang Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
LT2389352T (lt) 2009-01-26 2019-06-10 The Trustees Of The University Of Pennsylvania Arginazės inhibitoriai ir naudojimo būdai
SG10201503168VA (en) 2010-04-22 2015-06-29 Mars Inc Inhibitors of arginase and their therapeutic applications
HRP20160305T1 (hr) * 2010-10-26 2016-07-01 Mars, Incorporated Borati kao inhibitori arginaze
CA2824599C (en) 2010-12-31 2020-03-10 Astrazeneca Uk Limited Arginase inhibitors and methods of use thereof
WO2013059437A1 (en) 2011-10-19 2013-04-25 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
JP6073343B2 (ja) 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
CN104540836B (zh) * 2012-04-18 2016-11-09 马尔斯公司 作为精氨酸酶抑制剂的环约束类似物
TW201427664A (zh) * 2012-11-02 2014-07-16 Pharmacyclics Inc Tec家族激酶抑制劑佐劑療法
EA201690746A1 (ru) * 2013-10-25 2016-12-30 Фармасайкликс Элэлси Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
CN105879030A (zh) * 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
CN107405404A (zh) * 2015-03-20 2017-11-28 塞米·欧尤·奥皮约 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途
US10143699B2 (en) 2015-06-23 2018-12-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
SG11201802961PA (en) 2015-10-30 2018-05-30 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne

Similar Documents

Publication Publication Date Title
JP2018533582A5 (https=)
HRP20201046T1 (hr) Sastavi i metode za inhibitivnu aktivnost arginase
IL292677A (en) Preparations and methods for inhibiting arginase activity
JP2020514271A5 (https=)
ES2925564T3 (es) Derivados de azetidina tal como moduladores de receptores de quimiocinas y usos de los mismos
KR102781404B1 (ko) 통합 스트레스 경로의 조정제
JP2018162256A (ja) アポトーシス阻害タンパク質(iap)のアンタゴニスト
JP2010533206A5 (https=)
ES2941790T3 (es) Copolímeros dibloque autoensamblados compuestos de PEGMEMA y segmentos poliméricos portadores de fármacos
RU2013114848A (ru) Гуанидиновые соединения и композиции для ингибирования nampt
JP2019519599A (ja) 統合ストレス経路のモジュレーター
JP7427655B2 (ja) 精巣副腎残存腫瘍および卵巣副腎残存腫瘍を処置するための方法
TW201945356A (zh) 趨化介素受體調節劑及其用途
CN109641853A (zh) 整合应激通路的调节剂
EP3802544A1 (en) Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
WO2018049271A1 (en) Chemokine receptor modulators and uses thereof
JP2006507308A5 (https=)
JP2020510032A5 (https=)
JP2019194194A (ja) 癌を治療するためのhdac8阻害剤
KR20070010125A (ko) 인테그린과 선택적으로 결합하는 피페리디닐 표적화 화합물
JP2025525869A (ja) フェロトーシスを誘導するための組成物および方法
JP2023501038A (ja) 新規の治療的使用
JP2019536783A5 (https=)
JP2014505052A (ja) 癌の治療および予防用の新規なウレア
CN106459011B (zh) 作为抗肿瘤化合物的σ-2受体配体药物缀合物、其合成方法及其用途